antigen matched related or 6/6 HLA matched 
unrelated donor. 
2 . In patients who are candidates for an unrelated 
donor search through the registry, failure to find 
a match is implied if no compatible A, B donors 
are identified with the initial search, or, if the 
search process has continued unsuccessfully for 
six months. 
4.4 It is recommended that patients < age 45 be evaluated 
for allogeneic transplantation with an unrelated or 
related, matched donor; patients < 50 should be 
evaluated for allogeneic transplantation with a matched 
related donor only; since other factors may enter into 
this decision, the final judgement for allogeneic 
transplant is left to the discretion of the 
investigator. 
4.5 Patients must have 1st chronic phase CML, or be 
reinduced to chronic phase, prior to bone marrow and 
peripheral blood stem cell harvest. 
4.6 Patients may be transplanted in blast crisis, 
accelerated phase or chronic phase. Suggested 
diagnostic criteria for these phases is summarized: 
1. Accelerated Phase: (any one of the following) 
Failure of busulfan or hydrea to restore normal or 
near normal blood counts or to decrease 
splenomegaly. 
Rising basophil count to > 30% 
Increased blasts in marrow to 10-30% 
extramedullary granulocytic tumors 
- 2. Blast Phase: 
Increased blasts in the marrow to > 30% 
4.7 Patients must have a marrow cellularity > 30%. 
4.8 Patients with extensive marrow fibrosis which makes 
marrow aspiration difficult will be excluded from the 
study . 
4.9 Patients on interferon therapy should have this 
discontinued for > 4 weeks prior to high dose 
cytarabine and daunorubicin. 
4.10 The patient should be free of other serious medical 
disorders unrelated to leukemia such as liver disease 
(bilirubin <3.0), renal dysfunction (creatinine <2.0), 
significant chronic obstructive pulmonary disease (DLCO 
Recombinant DNA Research, Volume 16 
[155] 
